NBI-921352 is entering phase II proof-of-concept trials for the treatment of SCN8A-developmental epileptic encephalopathy (SCN8A-DEE) and adult focal-onset seizures. The gene discussed is SCN8A; the disease is developmental and epileptic encephalopathy.